In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Epigenomics completes €5.18mm stock sale

Executive Summary

Epigenomics (molecular diagnostics for cancer) grossed €5.18mm ($6.7mm) through the sale of 2.7mm new shares at €1.94 each (a 10% premium) to a subsidiary of BB Medtech AG and funds managed by Abingworth LLP. Now the investors each hold 14.9% and 11.1% stakes in the company, respectively. Epigenomics will use the funds to complete development and initiate commercialization of its blood test for colorectal cancer.
Deal Industry
  • In Vitro Diagnostics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies